Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach

Forty percent of patients with diffuse large B-cell lymphoma (DLBCL) show resistant disease to standard chemotherapy (CHOP) in combination with the anti-CD20 monoclonal antibody rituximab (R). Although many new anti-cancer drugs were developed in the last years, it is unclear which of these drugs ca...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Mathilde R. W., Visser, Lydia, Huls, Gerwin, Diepstra, Arjan, van Vugt, Marcel, Ammatuna, Emanuele, van Rijn, Rozemarijn S., Vellenga, Edo, van den Berg, Anke, Fehrmann, Rudolf S. N., van Meerten, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831110/
https://www.ncbi.nlm.nih.gov/pubmed/29489886
http://dx.doi.org/10.1371/journal.pone.0193098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831110/
https://www.ncbi.nlm.nih.gov/pubmed/29489886
http://dx.doi.org/10.1371/journal.pone.0193098

Ejemplares similares